Our findings refine this paradigm by demonstrating that dual anti-Ro52/Ro60 positivity—rather than isolated anti-Ro60 reactivity—drives the association with refractory disease, suggesting prior studies may have overlooked critical heterogeneity within anti-Ro-positive RA populations. This evidence concerns the gene TRIM21 and rheumatoid arthritis.